454464-55-2

Upstream product

• 19829-31-3 1-(3-bromophenyl)-1-propanone 
• 74380-71-5 3-hydroxycarbonyl-propiophenone 
• 50916-34-2 3-propionylbenzonitrile 
• 115006-21-8 3-propionyl-benzoic acid methyl ester 

Downstream Products

• 473548-66-2 3-(2,5-dimethyl-thiazol-4-yl)-benzoic acid methyl ester 
• 473538-04-4 3-(5-methyl-oxazol-4-yl)-benzoic acid methyl ester 
• 473548-64-0 3-(5-methyl-thiazol-4-yl)-benzoic acid methyl ester 
• 454464-87-0 3-[3-(3-chloro-phenylamino)-2-mercapto-5-methyl-3H-imidazol-4-yl]-benzoic acid 
• 454464-57-4 3-[3-(3-chloro-phenylamino)-2-mercapto-5-methyl-3H-imidazol-4-yl]-benzamide 
• 554449-47-7 3-(2-mercapto-5-methyl-3-m-tolylamino-3H-imidazol-4-yl)-benzamide 
• 656256-96-1 3-(3,3-dicyano-2-methyl-propionyl)-benzoic acid methyl ester 
• 454464-86-9 3-(2-mercapto-5-methyl-3-m-tolylamino-3H-imidazol-4-yl)-benzoic acid methyl ester 
• 454464-58-5 3-[3-(3-chloro-phenylamino)-2-mercapto-5-methyl-3H-imidazol-4-yl]-benzoic acid methyl ester 

Relevant academic research and scientific papers

PIPERIDINE-AMIDE DERIVATIVES

The invention is concerned with novel piperidine-amide derivatives of formula (I) wherein R1, R2, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These comp

Acid-mediated cyclization of 3-benzoyl-2-cyanobutyronitrile to 2-amino-4-methyl-5-phenylfuran-3-carbonitrile

Cyclization of 3-benzoyl-2-cyanobutyronitrile to 2-amino-4-methyl-5-phenylfuran-3-carbonitrile was effected under acidic conditions, rather than the basic conditions previously reported. Since treatment with trifluoroacetic acid (TFA) at room temperature is very mild, 2-amino-4-methyl-5-phenylfuran-3-carbonitriles containing various functional groups can be accessed via this route.

N-aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action

The synthesis of a series of N-aminoimidazoles (NAIMs) with an uncommon spectrum of antiretroviral activity is described. From a group of 60 closely related molecules, we were able to subdivide the molecules in different groups based on their anti-HIV and anti-SIV activity in vitro: (i) molecules acting on a new, immediate postintegration step, (ii) molecules acting on both postintegration and HIV-1 reverse transcriptase (RT) as NNRTI, and (iii) molecules that mainly act at the HIV-1 RT according to an NNRTI-type mode of action.

Dihydro-benzo [b][1,4]diazepin-2-one derivatives

This invention is a dihydro-benzo[b][1,4]diazepin-2-one derivative of the formula wherein R1, R2, R3, X and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation, their use in preparation of pharmaceutical compositions and administration of an effective amount of the compounds for the treatment or prevention of acute and/or chronic neurological disorders to a patient in need of such treatment.

Dihydro-benzo [b] [1,4] diazepin-2-one derivatives

This invention is a dihydro-benzo [b] [1,4] diazepin-2-one derivative of the formula wherein R1, R2, R3 and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation and a method of treatment or prevention of acute and/or chronic neurological disorders by administering an effective amount of the compound of formula I or a pharmaceuticall acceptable salt thereof.

Pyrrole derivatives and medicinal composition

The invention relates to a pharmaceutical composition comprising a pyrrole derivative of the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate of either of them, as an active ingredient. STR1 (wherein R1 represents hydrogen or alkoxycar91 bonylamino, R2 represents alkyl, aryl which may be substituted, aromatic heterocyclyl which may be substituted, unsubstituted amino, monoalkylamino, dialkylamino, or cyclic amino which may be substituted; R3 represents cyano or carbamoyl; R4 represents hydrogen or alkyl; E represents alkylene; q is equal to 0 or 1, A represents methyl, aryl which may be substituted, or aromatic heterocyclyl which may be substituted). The pharmaceutical composition of the invention is effective for the treatment of pollakiuria or urinary incontinence.